https://www.zacks.com/stock/news/2242497/novartis-nvs-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2242497
Mar 18, 2024 - In the latest trading session, Novartis (NVS) closed at $95.92, marking a -1.39% move from the previous day.
zc:-2085618326458777051
0
https://www.zacks.com/stock/news/2242089/down-14-35-in-4-weeks-here-s-why-galapagos-nv-glpg-looks-ripe-for-a-turnaround?cid=CS-ZC-FT-tale_of_the_tape|rsi-2242089
Mar 18, 2024 - Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zc:-4900464948980423759
0
https://seekingalpha.com/article/4678085-agfa-gevaert-nv-afgvf-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Mar 13, 2024 - AGFA Gevaert NV (OTCPK:AFGVF) Q4 2023 Earnings Conference Call March 13, 2024 6:00 AM ETCompany ParticipantsPascal Juery - President, CEO, President,...
0
sa:-2526978684865366892
0
https://www.zacks.com/stock/news/2239592/novartis-nvs-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2239592
Mar 12, 2024 - In the most recent trading session, Novartis (NVS) closed at $99.77, indicating a -1.58% shift from the previous trading day.
zc:4326410611442915939
0
https://www.zacks.com/stock/news/2238956/novartis-nvs-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2238956
Mar 11, 2024 - Novartis (NVS) closed the most recent trading day at $101.37, moving +0.66% from the previous trading session.
zc:-8340105195982078511
0
https://www.zacks.com/stock/news/2238200/what-makes-mainz-biomed-nv-mynz-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2238200
Mar 08, 2024 - Mainz Biomed NV (MYNZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zc:2752182196277331989
0
https://seekingalpha.com/article/4675447-bpost-nv-sa-bposf-q4-2023-earnings-call-transcript?source=feed_sector_transcripts
Mar 01, 2024 - bpost NV/SA (OTCPK:BPOSF) Q4 2023 Earnings Conference Call March 1, 2024 4:00 AM ETCompany ParticipantsChris Peeters - CEOPhilippe Dartienne - CFOConference...
0
sa:-2252782769598939050
0
https://www.fool.com/earnings/call-transcripts/2024/02/29/anheuser-busch-inbevnv-bud-q4-2023-earnings-call-t/?source=iedfolrf0000001
Feb 29, 2024 - BUD earnings call for the period ending December 31, 2023.
0
fool:2341111221201859107
0
https://www.zacks.com/stock/news/2228151/roche-s-rhhby-xolair-gets-approval-for-food-allergies?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2228151
Feb 19, 2024 - Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.
zc:2421545480960216920
0
https://www.zacks.com/stock/news/2227293/ionis-ions-olezarsen-gets-fda-s-orphan-tag-for-rare-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2227293
Feb 16, 2024 - FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.
zc:-4389715286765519151
0